Interim 18F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine.

Abstract

18F-fluoro-2-dexoy-D-glucose-positron emission tomography (PET)/computed tomography (CT) is a useful imaging technique for monitoring the treatment response in lymphoma cases. We investigated the value of interim brain PET/CT (I-PET/CT) for monitoring the response to intensive methotrexate-based chemotherapy in primary central nervous system lymphoma (PCNSL) patients with diffuse large B cell lymphoma (DLBCL). Of the 76 PCNSL patients treated with intensive methotrexate and cytarabine chemotherapy between September 2006 and December 2012, 66 patients with DLBCL were included in this study. The patient cohort of 66 individuals comprised 43 men and 23 women with a median age of 59 years (range, 17-75 years). During chemotherapy, 36 patients (54.5%) showed a negative metabolism on I-PET/CT, and 47 (71.2%) were negative on final (F) PET/CT. The baseline characteristics were similar between I-PET/CT-negative (n = 36) and I-PET/CT-positive patients (n = 30) except ECOG performance status. After a median follow-up of 27.5 months, there was no difference in the progression-free survival (PFS; P = 0.701) or overall survival (OS; P = 0.620) between the I-PET/CT-negative and I-PET/CT-positive groups. However, PFS in the F-PET/CT-negative group was significantly longer than that in the F-PET/CT-positive group (P < 0.001) without a significant difference in OS (P = 0.892). I-PET/CT may not predict the survival outcome of PCNSL patients with DLBCL treated with intensive methotrexate and cytarabine chemotherapy. Prospective trials are required to fully evaluate the role of I-PET/CT.

• Authors: Jae-Cheol Jo, Dok Hyun Yoon, Shin Kim, Kyoungmin Lee, Eun Hee Kang, Jung Sun Park, Jin-Sook Ryu, Jooryung Huh, Chan-Sik Park, Jong Hoon Kim, Sang Wook Lee, Cheolwon Suh
• Journal: Annals of hematology (Ann Hematol) Vol. 96 Issue 9 Pg. 1509-1515 (Sep 2017) ISSN: 1432-0584 [Electronic] Germany
• PMID: 28725988 (Publication Type: Journal Article)

Chemical References

• Cytarabine
• Fluorodeoxyglucose F18
• Methotrexate

Topics

• Adolescent
• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Central Nervous System Neoplasms (diagnostic imaging, drug therapy, mortality)
• Cytarabine (administration & dosage)
• Disease-Free Survival
• Female
• Fluorodeoxyglucose F18 (administration & dosage)
• Humans
• Lymphoma (diagnostic imaging, drug therapy, mortality)
• Male
• Methotrexate (administration & dosage)
• Middle Aged
• Positron-Emission Tomography
• Registries
• Retrospective Studies
• Survival Rate